Our results showed higher enrichment scores for the lymphocyte-specific kinase (LCK), major histocompatibility complex I (MHC-I), major histocompatibility complex II (MHC-II) and signal transducer and activator of transcription 1 (STAT1) metagenes in glioma patients with high ALKBH5 expression levels from the CGGA_325, CGGA_693, and TCGA datasets (Supplementary Figure 10). This evidence concerns the gene LCK and central nervous system cancer.